PPD Enhances Therapeutic Area Expertise for Global Product Development

WILMINGTON, N.C. – Pharmaceutical Product Development, LLC (PPD) today announced it has appointed Gregory Dennis, M.D., as vice president of global product development. In this role, Dr. Dennis serves as therapeutic area head, providing medical and scientific expertise for rheumatology, immunology and inflammatory diseases.

"Dr. Dennis brings extensive product development and commercialization experience and will play a key role in helping clients plan and address critical drug development challenges," said Rob Dow, M.B.Ch.B., F.R.C.P. (Edin), F.F.P.M., global head of medical affairs for PPD. "His background with biopharmaceutical companies and government agencies adds value to PPD's global clinical trial experience in a variety of rheumatology, immunology and inflammatory areas, including osteoarthritis, rheumatoid arthritis, gout, lupus and psoriasis."

Deep therapeutic area expertise is integral to PPD's comprehensive service offerings, including integrated laboratory, Phase I-IV and consulting services. PPD manages hundreds of clinical studies each year and leverages this expertise and experience to create optimal design decisions, efficient processes and economies of scale for clients.

Dr. Dennis comes to PPD from UCB, where he served as head of immunology for U.S. medical affairs and participated extensively in guiding compounds through the regulatory approval process. Previously, he held leadership roles at Human Genome Sciences, MedImmune and the National Institutes of Health. He retired from the U.S. Army Medical Corps as a colonel, chief of rheumatology and consultant to the army surgeon general.

Dr. Dennis earned a medical degree from St. Louis University and a bachelor's degree in biology from the University of Missouri.

Suggested Articles

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.